Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.

Tytuł :
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Autorzy :
Modi D; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA. .
Singh V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Kim S; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, 48201, USA.
Ayash L; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Deol A; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Ratanatharathorn V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Uberti JP; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Apr; Vol. 100 (4), pp. 969-978. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Comparative Study; Journal Article
Język :
English
Imprint Name(s) :
Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York : Springer International, c1991-
MeSH Terms :
Peripheral Blood Stem Cell Transplantation*
Antilymphocyte Serum/*therapeutic use
Busulfan/*therapeutic use
Graft vs Host Disease/*prevention & control
Immunosuppressive Agents/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Myeloablative Agonists/*therapeutic use
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Aged ; Allografts ; Busulfan/adverse effects ; Female ; Graft vs Host Disease/etiology ; Humans ; Infections/epidemiology ; Lymphocyte Depletion ; Male ; Middle Aged ; Mycophenolic Acid/therapeutic use ; Myeloablative Agonists/adverse effects ; Progression-Free Survival ; Retrospective Studies ; T-Lymphocytes ; Tacrolimus/therapeutic use ; Treatment Outcome ; Unrelated Donors ; Vidarabine/adverse effects ; Vidarabine/therapeutic use ; Whole-Body Irradiation
References :
Peccatori J, Ciceri F (2010) Allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 95(6):857–859. https://doi.org/10.3324/haematol.2010.023184. (PMID: 10.3324/haematol.2010.023184205138042878779)
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME (2017) Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 35(11):1154–1161. https://doi.org/10.1200/JCO.2016.70.7091. (PMID: 10.1200/JCO.2016.70.7091283803155455603)
Cahn JY, Labopin M, Schattenberg A, Reiffers J, Willemze R, Zittoun R, Bacigalupo A, Prentice G, Gluckman E, Herve P, Gratwohl A, Gorin NC (1997) Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 11(3):416–419. https://doi.org/10.1038/sj.leu.2400573. (PMID: 10.1038/sj.leu.24005739067582)
Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, Storb R, Gopal AK (2005) Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 23(15):3439–3446. https://doi.org/10.1200/JCO.2005.05.694. (PMID: 10.1200/JCO.2005.05.69415824415)
Zikos P, Van Lint MT, Frassoni F, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, De Stefano F, Soracco M, Vitale V, Bacigalupo A (1998) Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood 91(9):3503–3508. (PMID: 10.1182/blood.V91.9.3503)
Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ (2005) Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105(4):1810–1814. https://doi.org/10.1182/blood-2004-05-1947. (PMID: 10.1182/blood-2004-05-194715459007)
Farag SS, Maharry K, Zhang MJ, Perez WS, George SL, Mrozek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringden O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ, Acute Leukemia Committee of the Center for International B, Marrow Transplant R, Cancer, Leukemia Group B (2011) Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 17(12):1796–1803. https://doi.org/10.1016/j.bbmt.2011.06.005. (PMID: 10.1016/j.bbmt.2011.06.00521699879)
Gupta V, Daly A, Lipton JH, Hasegawa W, Chun K, Kamel-Reid S, Tsang R, Yi QL, Minden M, Messner H, Kiss T (2005) Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 11(10):764–772. https://doi.org/10.1016/j.bbmt.2005.06.006. (PMID: 10.1016/j.bbmt.2005.06.00616182177)
Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M (2003) Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102(8):3052–3059. https://doi.org/10.1182/blood-2003-03-0855. (PMID: 10.1182/blood-2003-03-085512842990)
Modi D, Deol A, Kim S, Ayash L, Alavi A, Ventimiglia M, Bhutani D, Ratanatharathorn V, Uberti JP (2017) Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. Bone Marrow Transplant 52(11):1530–1536. https://doi.org/10.1038/bmt.2017.182. (PMID: 10.1038/bmt.2017.182288696136857174)
Hill-Kayser CE, Plastaras JP, Tochner Z, Glatstein E (2011) TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant 46(4):475–484. https://doi.org/10.1038/bmt.2010.280. (PMID: 10.1038/bmt.2010.28021113184)
Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM (2010) Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 28(17):2859–2867. https://doi.org/10.1200/JCO.2009.27.1460. (PMID: 10.1200/JCO.2009.27.1460204396262903320)
Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA (2010) The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant 16(4):509–514. https://doi.org/10.1016/j.bbmt.2009.11.017. (PMID: 10.1016/j.bbmt.2009.11.01719948235)
Chen GL, Hahn T, Wilding GE, Groman A, Hutson A, Zhang Y, Khan U, Liu H, Ross M, Bambach B, Higman M, Neppalli V, Sait S, Block AW, Wallace PK, Singh AK, McCarthy PL (2019) Reduced-intensity conditioning with fludarabine, melphalan, and total body irradiation for allogeneic hematopoietic cell transplantation: the effect of increasing melphalan dose on underlying disease and toxicity. Biol Blood Marrow Transplant 25(4):689–698. https://doi.org/10.1016/j.bbmt.2018.09.042. (PMID: 10.1016/j.bbmt.2018.09.04230300731)
Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB (2017) Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing hla-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol 35(36):4003–4011. https://doi.org/10.1200/JCO.2017.75.8177. (PMID: 10.1200/JCO.2017.75.817729040031)
Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, Heim D, Bertz H, Grishina O, Socie G (2017) Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol 4(6):e293–e301. https://doi.org/10.1016/S2352-3026(17)30081-9. (PMID: 10.1016/S2352-3026(17)30081-928583289)
Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R, Canadian B, Marrow Transplant G (2016) Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 17(2):164–173. https://doi.org/10.1016/S1470-2045(15)00462-3. (PMID: 10.1016/S1470-2045(15)00462-326723083)
Ratanatharathorn V, Deol A, Ayash L, Cronin S, Bhutani D, Lum LG, Abidi M, Ventimiglia M, Mellert K, Uberti JP (2015) Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant 50(1):106–112. https://doi.org/10.1038/bmt.2014.203. (PMID: 10.1038/bmt.2014.20325285804)
Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Sacchi N, van Lint MT, Bosi A, Gruppo Italiano Trapianti Midollo O (2006) Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 12(5):560–565. https://doi.org/10.1016/j.bbmt.2005.12.034. (PMID: 10.1016/j.bbmt.2005.12.03416635791)
Devillier R, Furst S, El-Cheikh J, Castagna L, Harbi S, Granata A, Crocchiolo R, Oudin C, Mohty B, Bouabdallah R, Chabannon C, Stoppa AM, Charbonnier A, Broussais-Guillaumot F, Calmels B, Lemarie C, Rey J, Vey N, Blaise D (2014) Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. Biol Blood Marrow Transplant 20(3):370–374. https://doi.org/10.1016/j.bbmt.2013.11.030. (PMID: 10.1016/j.bbmt.2013.11.03024315846)
Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal M, Jindra P, Goker H, Socie G, Chevallier P, Browne P, Sandstedt A, Duarte RF, Nagler A, Mohty M (2014) Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 49 (3):389-396. doi:10.1038/bmt.2013.204.
Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, Devine S, Isola L, Lazarus HM, Marks DI, Porter DL, Waller EK, Horowitz MM, Eapen M (2011) Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117(25):6963–6970. https://doi.org/10.1182/blood-2011-01-332007. (PMID: 10.1182/blood-2011-01-332007214643723128486)
Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ, Storer BE, Appelbaum FR, Antin JH, Soiffer RJ, Kim HT (2012) A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 120(4):905–913. https://doi.org/10.1182/blood-2012-03-418202. (PMID: 10.1182/blood-2012-03-418202227096873412351)
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919. https://doi.org/10.1182/blood-2005-05-2004. (PMID: 10.1182/blood-2005-05-2004159942821895304)
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21(3):389–401 e381. https://doi.org/10.1016/j.bbmt.2014.12.001. (PMID: 10.1016/j.bbmt.2014.12.00125529383)
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18(4):295–304. (PMID: 10.1097/00007890-197410000-00001)
Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P, Ugarte-Torres A, Khan FM, Luider J, Auer-Grzesiak I, Mansoor A, Russell JA, Daly A, Stewart DA, Maloney D, Boeckh M, Storek J (2012) Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 14(10):1258–1275. https://doi.org/10.3109/14653249.2012.715243. (PMID: 10.3109/14653249.2012.715243229851953681879)
Bonnefoy-Berard N, Flacher M, Revillard JP (1992) Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. Blood 79(8):2164–2170. (PMID: 10.1182/blood.V79.8.2164.2164)
Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, Bozorgzadeh A, Sanz I, Briggs BJ (2005) Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79(11):1507–1515. https://doi.org/10.1097/01.tp.0000164159.20075.16. (PMID: 10.1097/01.tp.0000164159.20075.1615940039)
Haidinger M, Geyeregger R, Poglitsch M, Weichhart T, Zeyda M, Vodenik B, Stulnig TM, Bohmig GA, Horl WH, Saemann MD (2007) Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. Transplantation 84(1):117–121. https://doi.org/10.1097/01.tp.0000266677.45428.80. (PMID: 10.1097/01.tp.0000266677.45428.8017627247)
LaCorcia G, Swistak M, Lawendowski C, Duan S, Weeden T, Nahill S, Williams JM, Dzuris JL (2009) Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 87(7):966–974. https://doi.org/10.1097/TP.0b013e31819c84b8. (PMID: 10.1097/TP.0b013e31819c84b819352114)
Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R (2004) Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10(3):178–185. https://doi.org/10.1016/j.bbmt.2003.10.006. (PMID: 10.1016/j.bbmt.2003.10.00614993883)
Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL (1997) Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90(8):3204–3213. (PMID: 10.1182/blood.V90.8.3204)
Hill GR, Ferrara JL (2000) The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95(9):2754–2759. (PMID: 10.1182/blood.V95.9.2754.009k25_2754_2759)
Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Barbanti M, Sacchi N, Van Lint MT, Bosi A (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98(10):2942–2947. https://doi.org/10.1182/blood.v98.10.2942. (PMID: 10.1182/blood.v98.10.294211698275)
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhauser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socie G, Group AT-FT (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855–864. https://doi.org/10.1016/S1470-2045(09)70225-6. (PMID: 10.1016/S1470-2045(09)70225-619695955)
Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM (2009) Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant 15(11):1422–1430. https://doi.org/10.1016/j.bbmt.2009.07.006. (PMID: 10.1016/j.bbmt.2009.07.006198223023953136)
Devillier R, Crocchiolo R, Castagna L, Furst S, El Cheikh J, Faucher C, Prebet T, Etienne A, Chabannon C, Vey N, Esterni B, Blaise D (2012) The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 47(5):639–645. https://doi.org/10.1038/bmt.2012.3. (PMID: 10.1038/bmt.2012.322307016)
Malard F, Cahu X, Clavert A, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Miplied N, Le Gouill S, Mohty M (2011) Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. Biol Blood Marrow Transplant 17(11):1698–1703. https://doi.org/10.1016/j.bbmt.2011.04.010. (PMID: 10.1016/j.bbmt.2011.04.01021601642)
Contributed Indexing :
Keywords: Acute myeloid leukemia (AML); Allogeneic stem cell transplantation; Myeloablative conditioning regimen; Reduced intensity conditioning regimen; Thymoglobulin (ATG); Unrelated donor transplant
Substance Nomenclature :
0 (Antilymphocyte Serum)
0 (Immunosuppressive Agents)
0 (Myeloablative Agonists)
D7RD81HE4W (thymoglobulin)
FA2DM6879K (Vidarabine)
G1LN9045DK (Busulfan)
HU9DX48N0T (Mycophenolic Acid)
P2K93U8740 (fludarabine)
WM0HAQ4WNM (Tacrolimus)
Entry Date(s) :
Date Created: 20210217 Date Completed: 20210325 Latest Revision: 20210325
Update Code :
20210326
DOI :
10.1007/s00277-021-04445-8
PMID :
33594448
Czasopismo naukowe
A head-to-head comparison of outcomes of unrelated donor allogeneic peripheral blood stem cell transplantation for AML between reduced intensity conditioning (RIC) and myeloablative conditioning (MAC) regimens using thymoglobulin for GVHD prophylaxis is limited. We evaluated outcomes of 122 AML patients who received either busulfan (Bu)/fludarabine (Flu)/low-dose total body irradiation (TBI) as RIC (n = 64, 52%) or Bu/Flu as MAC (n = 58, 48%), and thymoglobulin 4.5 mg/kg total dose between day - 3 to - 1 for GVHD prophylaxis. Grades III-IV acute GVHD (aGVHD) was lower with Bu/Flu/TBI compared with Bu/Flu (6.2% vs 26.1%, p = 0.009). At 1 year, Bu/Flu/TBI was associated with similar chronic GVHD (41.2% vs 44.8%, p = 0.75), OS (61.9% vs 56.9%, p = 0.69), relapse rate (29.9% vs 20.7%, p = 0.24), relapse-free survival (52.8% vs 50%, p = 0.80), non-relapse mortality (17.4% vs 29.3%, p = 0.41), and GVHD-free relapse-free survival (24.2% vs 27.5%, p = 0.80) compared with Bu/Flu. Multivariable analysis did not reveal any difference in outcomes between both regimens. In summary, thymoglobulin at 4.5 mg/kg did not have any adverse impact on survival when used with RIC regimen. Both Bu/Flu/TBI and Bu/Flu conditioning regimens yielded similar survival.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies